Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy

被引：72
作者：
Queirolo, Paola [1 ]
Boutros, Andrea [1 ]
Tanda, Enrica [1 ]
Spagnolo, Francesco [1 ]
Quaglino, Pietro [2 ]
机构：
[1] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy
[2] Univ Turin, Med Sch, Dept Med Sci, Dermatol Clin, Turin, Italy
来源：
SEMINARS IN CANCER BIOLOGY | 2019年 / 59卷
关键词：
Melanoma; Immunotherapy; Immune-checkpoint inhibitors; CTLA-4; PD-1; Biomarker; CUTANEOUS ADVERSE EVENTS; OPEN-LABEL; COMBINED NIVOLUMAB; TUMOR RESPONSE; CHECKMATE; 037; DOUBLE-BLIND; IPILIMUMAB; PEMBROLIZUMAB; SURVIVAL; PHASE-3;
D O I：
10.1016/j.semcancer.2019.08.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.
引用
收藏
页码：290 / 297
页数：8
相关论文
共 72 条
  • [1] Andtbacka RHI, 2013, J CLIN ONCOL, V31
  • [2] Ascierto A., 2018, KEYNOTE 022 3
  • [3] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
    Ascierto, Paolo A.
    Long, Georgina V.
    Robert, Caroline
    Brady, Benjamin
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Mortier, Laurent
    Hassel, Jessica C.
    Rutkowski, Piotr
    McNeil, Catriona
    Kalinka-Warzocha, Ewa
    Savage, Kerry J.
    Hernberg, Micaela M.
    Lebbe, Celeste
    Charles, Julie
    Mihalcioiu, Catalin
    Chiarion-Sileni, Vanna
    Mauch, Cornelia
    Cognetti, Francesco
    Ny, Lars
    Arance, Ana
    Svane, Inge Marie
    Schadendorf, Dirk
    Gogas, Helen
    Saci, Abdel
    Jiang, Joel
    Rizzo, Jasmine
    Atkinson, Victoria
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 187 - 194
  • [4] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Ascierto, Paolo A.
    Del Vecchio, Michele
    Robert, Caroline
    Mackiewicz, Andrzej
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Bastholt, Lars
    Hamid, Omid
    Rutkowski, Piotr
    McNeil, Catriona
    Garbe, Claus
    Loquai, Carmen
    Dreno, Brigitte
    Thomas, Luc
    Grob, Jean-Jacques
    Liszkay, Gabriella
    Nyakas, Marta
    Gutzmer, Ralf
    Pikiel, Joanna
    Grange, Florent
    Hoeller, Christoph
    Ferraresi, Virginia
    Smylie, Michael
    Schadendorf, Dirk
    Mortier, Laurent
    Svane, Inge Marie
    Hennicken, Delphine
    Qureshi, Anila
    Maio, Michele
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 611 - 622
  • [5] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
    Ascierto, Paolo Antonio
    Ferrucci, Pier Francesco
    Fisher, Rosalie
    Del Vecchio, Michele
    Atkinson, Victoria
    Schmidt, Henrik
    Schachter, Jacob
    Queirolo, Paola
    Long, Georgina V.
    Di Giacomo, Anna Maria
    Svane, Inge Marie
    Lotem, Michal
    Bar-Sela, Gil
    Couture, Felix
    Mookerjee, Bijoyesh
    Ghori, Razi
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Ribas, Antoni
    [J]. NATURE MEDICINE, 2019, 25 (06) : 941 - +
  • [6] Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.
    Ascierto, Paolo Antonio
    Melero, Ignacio
    Bhatia, Shailender
    Bono, Petri
    Sanborn, Rachel E.
    Lipson, Evan J.
    Callahan, Margaret K.
    Gajewski, Thomas
    Gomez-Roca, Carlos A.
    Hodi, F. Stephen
    Curigliano, Giuseppe
    Nyakas, Marta
    Preusser, Matthias
    Koguchi, Yoshinobu
    Maurer, Matthew
    Clynes, Raphael
    Mitra, Priyam
    Suryawanshi, Satyendra
    Munoz-Couselo, Eva
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity
    Barzaghi, Federica
    Passerini, Laura
    Bacchetta, Rosa
    [J]. FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [8] A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
    Bentebibel, Salah-Eddine
    Hurwitz, Michael E.
    Bernatchez, Chantale
    Haymaker, Cara
    Hudgens, Courtney W.
    Kluger, Harriet M.
    Tetzlaff, Michael T.
    Tagliaferri, Mary A.
    Zalevsky, Jonathan
    Hoch, Ute
    Fanton, Christie
    Aung, Sandra
    Hwu, Patrick
    Curti, Brendan D.
    Tannir, Nizar M.
    Sznol, Mario
    Diab, Adi
    [J]. CANCER DISCOVERY, 2019, 9 (06) : 711 - 721
  • [9] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
    Bertrand, Anne
    Kostine, Marie
    Barnetche, Thomas
    Truchetet, Marie-Elise
    Schaeverbeke, Thierry
    [J]. BMC MEDICINE, 2015, 13
  • [10] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
12345678